Portola to Initiate Phase 2 Study Evaluating the Safety and Effectiveness of Its Factor Xa Inhibitor Antidote PRT4445 in Reversing the Anticoagulant Activity of Investigational Factor Xa Inhibitor Edoxaban
Paul Quintaro